ArticleBritish journal of haematology2022
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Article in British journal of haematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy.Hematology. American Society of Hematology. Education Program · 2022Pooled it
- Pulmonary embolism associated with CRBN-targeting immunomodulatory drugs: a FAERS-based pharmacovigilance and mechanistic analysis.Journal of thrombosis and thrombolysis · 2026Article
- Article
- Universal Use of Novel Oral Anticoagulant Prophylaxis in Myeloma Patients Undergoing IMiD-Based Therapy: Real-World Experience.Journal of clinical medicine · 2026Article
- Thromboembolism and bleeding in newly diagnosed multiple myeloma: rates, risk profile, and patterns of thromboprophylaxis.Research and practice in thrombosis and haemostasis · 2025Article
- Article
- A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma.Research and practice in thrombosis and haemostasis · 2025Review
- Study on Risk Factors and Treatment Strategies for Deep Vein Thrombosis in Patients with Multiple Myeloma.Cancer management and research · 2025Review
- Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.Clinical hematology international · 2025Review
- Supportive care in myeloma-when treating the clone alone is not enough.Hematology. American Society of Hematology. Education Program · 2024Review
- Multiple myeloma: retrospective assessment of routine thromboprophylaxis and utility of thrombotic risk scores.Research and practice in thrombosis and haemostasis · 2024Article
- Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines.Annals of hematology · 2024Review
- Cancer-associated thrombosis in hematologic malignancies.International journal of hematology · 2024Review
- Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials.Therapeutic advances in medical oncology · 2024Article
- Lenalidomide use in multiple myeloma (Review).Molecular and clinical oncology · 2024Review
- Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.Blood cancer journal · 2023Article
- Pulmonary hypertension in patients with multiple myeloma: A comprehensive review.Pulmonary circulation · 2023Review
- Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma.Research square · 2023Article
- Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.Annals of medicine · 2023Article
- Nursing management of treatment-related venous thromboembolism in patients with multiple myeloma.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
Incidence of venous thromboembolism (VTE) varies across different regimens in newly diagnosed multiple myeloma (NDMM) patients. Limited data exist on the use of direct oral anticoagulants as thromboprophylaxis in the setting of haematologic malignancies, specifically multiple myeloma. In this retrospective study of 305 NDMM patients, VTE rates in those treated with carfilzomib, lenalidomide, dexamethasone (KRD) + aspirin (ASA), bortezomib, lenalidomide, dexamethasone (RVD) + ASA, and KRD + rivaroxaban were statistically significant, 16·1%, 4·8%, and 4·8%, respectively. The findings confirm a higher incidence of VTE when using KRD induction compared to RVD induction and reveal that the use of low-dose rivaroxaban thromboprophylaxis can mitigate this risk without an observable increase in bleeding rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.